eXoZymes, Inc. Total Assets
eXoZymes, Inc. total assets. Based on the latest financial reports, eXoZymes, Inc. (EXOZ) holds total assets worth $4.02 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of eXoZymes, Inc. for the company's overall valuation and market capitalisation.
Total Assets of eXoZymes, Inc. (2021–2025)
Total assets of eXoZymes, Inc. from 2021 to 2025. This chart illustrates how eXoZymes, Inc.'s total assets have evolved over time, based on quarterly financial data. See EXOZ live share price for real-time trading data and today's change.
eXoZymes, Inc. - Asset Composition Analysis
eXoZymes, Inc. Total Assets Breakdown (December 2025)
eXoZymes, Inc. total assets breakdown as of December 2025. eXoZymes, Inc.'s total assets of $4.02 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 50.9% |
| Accounts Receivable | $517.36K | 8.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how eXoZymes, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore EXOZ net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: eXoZymes, Inc.'s current assets represent 66.0% of total assets in 2025, an increase from 44.6% in 2021.
- Cash Position: Cash and equivalents constituted 50.9% of total assets in 2025, up from 23.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 8.7% of total assets.
eXoZymes, Inc. Competitors by Total Assets
Key competitors of eXoZymes, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
USA | $1.74 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
PYC Therapeutics Ltd
AU:PYC
|
Australia | AU$183.28 Million |
eXoZymes, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.32 | 6.52 | 2.32 |
| Quick Ratio | 1.32 | 6.52 | 2.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $507.58K | $7.97 Million | $834.88K |
eXoZymes, Inc. - Advanced Valuation Insights
This section examines the relationship between eXoZymes, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 51.88 |
| Latest Market Cap to Assets Ratio | 6.07 |
| Asset Growth Rate (YoY) | -54.2% |
| Total Assets | $5.97 Million |
| Market Capitalization | $36.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values eXoZymes, Inc.'s assets at a significant premium (6.07x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: eXoZymes, Inc.'s assets decreased by 54.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for eXoZymes, Inc. (2021–2025)
The table below shows the annual total assets of eXoZymes, Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.97 Million | -54.19% |
| 2024-12-31 | $13.03 Million | +266.29% |
| 2023-12-31 | $3.56 Million | +32.50% |
| 2022-12-31 | $2.69 Million | +14.47% |
| 2021-12-31 | $2.35 Million | -- |
About eXoZymes, Inc.
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.